期刊
MOLECULAR CELL
卷 28, 期 1, 页码 15-27出版社
CELL PRESS
DOI: 10.1016/j.molcel.2007.09.010
关键词
-
资金
- NCI NIH HHS [R01 CA068490-09, R01 CA068490, R01 CA068490-06, R01 CA068490-07, R01 CA068490-12, R01 CA068490-11A1, T32 CA009172, R01 CA068490-08, R01 CA068490-10] Funding Source: Medline
The VHL tumor suppressor protein (pVHL) is part of an E3 ubiquitin ligase that targets HIF for destruction. pVHL-defective renal carcinoma cells exhibit increased NF-B-K activity but the mechanism is unclear. NF-KB affects tumorigenesis and therapeutic resistance in some settings. We found that pVHL associates with the NF-KB agonist Card9 but does not target Card9 for destruction. Instead, pVHL serves as an adaptor that promotes the phosphorylation of the Card9 C terminus by CK2. Elimination of these sites markedly enhanced Card9's ability to activate NF-B-K in VHL+/+ cells, and Card9 siRNA normalized NF-B-K activity in VHL-/- cells and restored their sensitivity to cytokine-induced apoptosis. Furthermore, downregulation of Card9 in VHL-/- cancer cells reduced their tumorigenic potential. Therefore pVHL can serve as an adaptor for both a ubiquitin conjugating enzyme and a kinase. The latter activity, which promotes Card9 phosphorylation, links pVHL to control of NF-B-K activity and tumorigenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据